In the study, Symptom Management After Reducing Therapy (SMART-1
327 patients with BPH were treated with the combination of an a1-blocker (tamsulosin, 0.4 mg/d) plus a 5 a-reductase inhibitor (dutasteride, 0.5 mg/d).
In the study, Symptom Management After Reducing Therapy (SMART-1
327 patients with BPH were treated with the combination of an a1-blocker (tamsulosin, 0.4 mg/d) plus a 5 a-reductase inhibitor (dutasteride, 0.5 mg/d).